{"disease":{"id":"breast-neoplasms","name":"Breast Neoplasms","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":2,"trial_count":25},"drugs":{"marketed":[{"drug_id":"sacituzumab-govitecan","indication_name":"Triple negative breast neoplasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trodelvy","generic_name":"sacituzumab-govitecan","company_name":"Immunomedics Inc","drug_phase":"marketed","molecular_target":"Tumor-associated calcium signal transducer 2","drug_class":"","quality_score":68,"revenue":"800","mechanism":"Trodelvy works by binding to the TACI receptor on cancer cells, triggering a cascade of events that ultimately leads to cell death."},{"drug_id":"pembrolizuma","indication_name":"Triple negative breast neoplasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"pf-07260437","indication_name":"Advanced or metastatic solid tumors (including ovarian, endometrial, and breast neoplasms)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07260437","generic_name":"pf-07260437","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Unknown","drug_class":"Unknown oncology compound","quality_score":null,"revenue":null,"mechanism":"Mechanism of action unknown; experimental oncology compound discontinued during Phase 1 development."},{"drug_id":"palbociclib-plus-fulvestrant","indication_name":"Breast Neoplasms","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"palbociclib plus fulvestrant","generic_name":"palbociclib-plus-fulvestrant","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Patients treated with the combination of palbociclib and fulvestrant","quality_score":null,"revenue":null,"mechanism":"Patients treated with the combination of palbociclib and fulvestrant"},{"drug_id":"palbociclib-endocrine-therapy","indication_name":"Breast Neoplasms","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib + endocrine therapy","generic_name":"palbociclib-endocrine-therapy","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib +","quality_score":null,"revenue":null,"mechanism":"Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib +"}],"offLabel":[],"totalMarketed":2,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT06187350","title":"The Use of AI to Safely Reduce the Workload in Breast Cancer Screening With Mammography in Region Östergötland","phase":"","overall_status":"COMPLETED","enrollment_count":60000,"lead_sponsor_name":"Ostergotland County Council, Sweden","has_results":false},{"nct_id":"NCT03669926","title":"The Tomosynthesis Trial in Bergen - Part 2","phase":"NA","overall_status":"COMPLETED","enrollment_count":31082,"lead_sponsor_name":"Norwegian Institute of Public Health","has_results":false},{"nct_id":"NCT06591039","title":"A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03471494","title":"GlobalSurg 3: Quality and Outcomes in Global Cancer Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":15958,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT05675085","title":"Risk-Based Breast Screening in Young Women","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10269,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT04075305","title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT03257839","title":"Delphinus SoftVue Prospective Case Collection - ARM 1","phase":"","overall_status":"COMPLETED","enrollment_count":7409,"lead_sponsor_name":"Delphinus Medical Technologies, Inc.","has_results":false},{"nct_id":"NCT00341458","title":"Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics","phase":"","overall_status":"COMPLETED","enrollment_count":6086,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06856616","title":"Predicting Long-Term Clinical Outcomes in Chinese Breast Cancer Patients Receiving Neoadjuvant Chemotherapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"The Third Affiliated Hospital of Harbin Medical University","has_results":false},{"nct_id":"NCT05243121","title":"Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening and Diagnosis of Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT01661023","title":"The Ghana Breast Health Study","phase":"","overall_status":"COMPLETED","enrollment_count":4241,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT07214610","title":"Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":3300,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06830720","title":"A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence","phase":"","overall_status":"RECRUITING","enrollment_count":3250,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07010939","title":"A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"FangYi","has_results":false},{"nct_id":"NCT07149636","title":"Health Belief Model-Based Survey on Breast Self-Examination Awareness and Practice Among Community-Dwelling Middle-Aged and Older Women","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04985253","title":"Correlation of Predictive Accuracy of PREDICT Version 2.2 of Indian Women With Operable Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":2780,"lead_sponsor_name":"Tata Memorial Centre","has_results":false},{"nct_id":"NCT01566721","title":"A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2577,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06966700","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04585074","title":"Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Severance Hospital","has_results":false},{"nct_id":"NCT07581834","title":"Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT07096024","title":"A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market","phase":"","overall_status":"COMPLETED","enrollment_count":1772,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05797545","title":"Comparison of Ultrasound and Breast MRI for Breast Cancer Detection","phase":"NA","overall_status":"RECRUITING","enrollment_count":1756,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04085510","title":"Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1647,"lead_sponsor_name":"Wendie Berg","has_results":false},{"nct_id":"NCT03301493","title":"Genomic Testing and Resulting Medical Decisions","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","has_results":false},{"nct_id":"NCT01572038","title":"A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1436,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04767594","title":"First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1407,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07491055","title":"Wide-Angle Tomosynthesis and AI in Diagnostic Mammography","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Jean Seely","has_results":false},{"nct_id":"NCT07500428","title":"Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models","phase":"","overall_status":"RECRUITING","enrollment_count":1380,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT00073528","title":"Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1286,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06312176","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03036488","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1174,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02977247","title":"Delphinus SoftVue Prospective Case Collection - ARM 2","phase":"","overall_status":"COMPLETED","enrollment_count":1150,"lead_sponsor_name":"Delphinus Medical Technologies, Inc.","has_results":false},{"nct_id":"NCT06624020","title":"A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia","phase":"","overall_status":"COMPLETED","enrollment_count":1128,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05443672","title":"Multi-center Study of Deep Learning AI in Breast Mass","phase":"","overall_status":"UNKNOWN","enrollment_count":1122,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06026176","title":"Pattern of Clinical Presentation of Different Breast Disease in Surgical Opd at BPKIHS","phase":"","overall_status":"COMPLETED","enrollment_count":1023,"lead_sponsor_name":"B.P. Koirala Institute of Health Sciences","has_results":false},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT01959386","title":"A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1006,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06728527","title":"PARTial BREast RECONstruction With Chest Wall Perforator Flap","phase":"","overall_status":"RECRUITING","enrollment_count":1001,"lead_sponsor_name":"Cambridge University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT07060807","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06841354","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06938373","title":"Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT04603209","title":"Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Saint John's Cancer Institute","has_results":false},{"nct_id":"NCT05326295","title":"Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT06833723","title":"Development of a Multi-omics Prediction Model for Immunotherapy Response in Triple-Negative Breast Cancer Subtypes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences","has_results":false},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05113251","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":927,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03997123","title":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":923,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05346224","title":"A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":900,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT00092183","title":"An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":866,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}